Approval · Notice of Compliance 16150 · 2014
INVIRASE: Notice of Compliance 16150
Issued September 18, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16150
- Date
- September 18, 2014
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Dosing recommendations for treatment-naive patients when initiating treatment
- Therapeutic class
- HIV protease inhibitor / antiretroviral agent
Products in this notice
Medicinal ingredients
- SAQUINAVIR MESYLATE 200 MG per CAP
- SAQUINAVIR MESYLATE 500 MG per TAB